A basic study design for expedited safety signal evaluation based on electronic healthcare data

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 8, 2010, Pages 858-868

  Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cohort study; Healthcare databases; Incident user design; Pharmacoepidemiology; Propensity scores; Sentinel system

Indexed keywords

CONFERENCE PAPER; DRUG MONITORING; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COHORT STUDIES; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; DRUG MONITORING; DRUG TOXICITY; FEMALE; HUMANS; MALE; PRESCRIPTION DRUGS; PRIMARY HEALTH CARE; PROPENSITY SCORE;

EID: 77956625112     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1926     Document Type: Conference Paper

References (37)

1. Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network - improving the evidence of medical-product safety. N Engl J Med 2009; 361: 645-647.
2. Avorn J, Schneeweiss S. Managing drug-risk information - what to do with all those new numbers. N Engl J Med 2009; 361: 647-649.
3. US Food and Drug Administration: FDA's Sentinel Initiative. http:// www.fda.gov/Safety/FDAsSentinelInitiative/default.htm.
4. Walker AM. Orthogonal predictions: follow-up questions for suggestive data. Pharmacoepidemiol Drug Saf 2010; in press.
5. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology 2005; 16: 17-24.
6. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 2003; 92: 1447-1451.
7. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000; 21: 121-145.
8. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-153.
9. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-337.
10. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
11. Schneeweiss S, Patrick AR, Sturmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med care 2007; 45: S131-S142.
12. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009; 20: 488-495.
13. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-499.
14. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-737.
15. Solomon DH, Lunt M, Schneeweiss S. The risk of infection associated with tumor necrosis factor a antagonists: making sense of epidemiologic evidence. Arthritis Rheum 2008; 58: 919-928.
16. Wacholder S. Practical considerations in choosing between the case-cohort and nested case-control designs. Epidemiology 1991; 2: 155-158.
17. McMahon AD, Evans JM, McGilchrist MM, McDevitt DG, MacDonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 1998; 7: 275-280.
18. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004; 148: 99-104.
19. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-46.
20. Lagakos SW. The challenge of subgroup analyses - reporting without distorting. N Engl J Med 2006; 354: 1667-1669.
21. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 2003; 12: 551-558.
22. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291-303.
23. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163: 1149-1156.
24. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512-522.
25. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008; 27: 2037-2049.
26. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity- based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163: 262-270.
27. Lunt M, Solomon D, Rothman K, et al. Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. Am J Epidemiol 2009; 169: 909-917.
28. Sekula P, Caputo A, Dunant A, et al. An application of propensity score methods to estimate the treatment effect of corticosteroids in patients with severe cutaneous adverse reactions. Pharmacoepidemiol Drug Saf 2010; 19: 10-18.
29. Piantadosi S. Clinical Trials - A Methodologic Perspective. Wiley: New York, 1997.
30. Hernan MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008; 19: 766-779.
31. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; 17: 268-275.
32. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.[see comment][erratum appears in CMAJ. 2007 May 22;176(11):1613].CMAJ 2007; 176: 627-632.
33. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol 1976; 103: 226-235.
34. Wacholder S. The case-control study as data missing by design: estimating risk differences. Epidemiology 1996; 7: 144-150.
35. Rothman KJ. Modern Epidemiology (3rd Edition) Lippincott Williams & Wilkins: Philadelphia, 2008.
36. Roumie CL, Choma NN, Kaltenbach L, Mitchel EF Jr, Arbogast PG, Griffin MR. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf 2009; 18: 1053-1063.
37. Robins JM. Correcting for non-compliance in randomized trials using structural nested mean models. Commun Stat Theory Methods 1994; 23: 2379-2412.